Experience with febuxostat in a patient with severe disabling gout
Gout is a chronic disease that frequently leads to disability if urate-lowering therapy is inefficient. The paper presents the positive experience with febuxostat, a novel non-purine xanthine oxidase inhibitor, in a young patient with disabling chronic tophaceous gout. Twelve-month therapy with dail...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2017-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/779 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691599189049344 |
|---|---|
| author | M. S. Eliseev R. U. Shayakhmetova |
| author_facet | M. S. Eliseev R. U. Shayakhmetova |
| author_sort | M. S. Eliseev |
| collection | DOAJ |
| description | Gout is a chronic disease that frequently leads to disability if urate-lowering therapy is inefficient. The paper presents the positive experience with febuxostat, a novel non-purine xanthine oxidase inhibitor, in a young patient with disabling chronic tophaceous gout. Twelve-month therapy with daily 80-mg dose of febuxostat resulted in almost complete resorption of subcutaneous tophi and in a long-term lack of arthritis attacks with the persistent serum uric acid levels below target ones. This is the first experience in successfully switching from one to another xanthine oxidase inhibitor, which was described after febuxostat registration in the Russian Federation. |
| format | Article |
| id | doaj-art-2be0a3f7aa3a444193cd92bac49449a1 |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2017-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-2be0a3f7aa3a444193cd92bac49449a12025-08-20T03:20:59ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2017-09-01113818410.14412/1996-7012-2017-3-81-842052Experience with febuxostat in a patient with severe disabling goutM. S. Eliseev0R. U. Shayakhmetova1V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyGout is a chronic disease that frequently leads to disability if urate-lowering therapy is inefficient. The paper presents the positive experience with febuxostat, a novel non-purine xanthine oxidase inhibitor, in a young patient with disabling chronic tophaceous gout. Twelve-month therapy with daily 80-mg dose of febuxostat resulted in almost complete resorption of subcutaneous tophi and in a long-term lack of arthritis attacks with the persistent serum uric acid levels below target ones. This is the first experience in successfully switching from one to another xanthine oxidase inhibitor, which was described after febuxostat registration in the Russian Federation.https://mrj.ima-press.net/mrj/article/view/779gouturic acidtophixanthine oxidase inhibitorfebuxostat |
| spellingShingle | M. S. Eliseev R. U. Shayakhmetova Experience with febuxostat in a patient with severe disabling gout Современная ревматология gout uric acid tophi xanthine oxidase inhibitor febuxostat |
| title | Experience with febuxostat in a patient with severe disabling gout |
| title_full | Experience with febuxostat in a patient with severe disabling gout |
| title_fullStr | Experience with febuxostat in a patient with severe disabling gout |
| title_full_unstemmed | Experience with febuxostat in a patient with severe disabling gout |
| title_short | Experience with febuxostat in a patient with severe disabling gout |
| title_sort | experience with febuxostat in a patient with severe disabling gout |
| topic | gout uric acid tophi xanthine oxidase inhibitor febuxostat |
| url | https://mrj.ima-press.net/mrj/article/view/779 |
| work_keys_str_mv | AT mseliseev experiencewithfebuxostatinapatientwithseveredisablinggout AT rushayakhmetova experiencewithfebuxostatinapatientwithseveredisablinggout |